期刊文献+

脓毒症患者CD_(14)^+单核细胞人类白细胞抗原-DR表达的观察 被引量:6

Observation of the expression of CD_(14)^+ monocyte human leukocyte antigen DR in septic patients
下载PDF
导出
摘要 目的通过研究脓毒症患者静脉血CD14+单核细胞人类白细胞抗原-DR(HLA-DR)表达百分率的变化,评价患者的免疫状态及与疾病的严重程度和预后的关系。方法在患者被诊断为脓毒症后的第1、4、7、14、28天或出ICU及死亡前最后一次抽取静脉血,用流式细胞仪测定CD14+单核细胞HLA-DR表达百分率及当天的APACHEⅡ评分和SOFA评分,至脓毒症消失。结果18例患者存活,26例死亡。从第4天开始,存活组CD14+单核细胞HLA-DR表达均高于死亡组(P<0.001)。第1天、第4天CD14+单核细胞HLA-DR表达>30%者生存率均明显高于表达<30%者。CD14+单核细胞HLA-DR表达与APACHEⅡ评分、SOFA评分均存在负相关。结论脓毒症患者CD14+单核细胞HLA-DR表达持续低下可提示患者处于免疫抑制状态。检测CD14+单核细胞HLA-DR表达可用于判断脓毒症患者病情的严重程度和评估预后。 Objective To monitor the changes of the expression of CD14^+ monocyte human leukocyte antigen DR( HLA--DR) in septic patients and evaluate their immunological condition, relationship between severity of illness, prognosis and CD14^+ monocyte HLA--DR. Methods After the diagnosis of sepsis was made, patients'APACHE H-scores, SOFA scores and CD14^+ monocyte HLA--DR were determined in the 1st, 4th, 7th, 14th and 28th days or the last time in ICU. Results Total1y,44 patients were enrolled in this study. Among them 18 survived and 26 died. From the 4th day, the expression of CD14^+ monocyte HLA--DR in the survivors were significantly higher than that in the dead (P〈0.001) . Survival rate was greatly higher when CD14^+ monocyte HLA--DR was 〉30% in the 1st and 4th daies. There was a negative correlation between CD14^+ monocyte HLA--DR and APACHEll scores, SOFA scores. Conclusions Persistent low level of the expression of CD14^+ monocyte HLA--DR in septic patients show the patients were in the states of immunosuppression. Detection the expression of CD14^+ monocyte HLA-DR can be used to evaluate the severity of disease and predict prognosis in sepsis.
出处 《中国急救医学》 CAS CSCD 北大核心 2006年第4期249-251,共3页 Chinese Journal of Critical Care Medicine
关键词 脓毒症 代偿性抗炎症反应综合征 CD14^+ 单核细胞人类白细胞抗原-DR 预后 Sepsis Compensatory anti--inflammatory response syndrome(CARS) CD14^+ monocyte human leukocyte antigen DR Prognosis
  • 相关文献

参考文献8

  • 1Tslotou AG,Sakorafas GH,Anagnostopoulos G,et a l.Septic shock;current pathogenetic concepts from a clinical perspective[J].Med Sci Monit,2005,11(3):RA76-85.
  • 2Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Crit Care Med,1992,20:864-872.
  • 3Bone RC.Sir Isaac Newton,sepsis,SIRS,and CARS[J].Crit Care Med,1996,24:1125-1128.
  • 4Richard S,Hotchkiss MD,Irene E,et al.The pathophysiology and treatment of sepsis[J].New Engl J Med,2003,348:138.
  • 5Volk HD,Thieme M,Heym S,et al.Alterations in function and phenotype of monocytes from patients with septic diseasepredictive value and new therapeutic strategies[J].Behring Inst Mitt,1991,88:208-215.
  • 6林洪远,郭旭生,姚咏明,程尉新,翁志华,韦文韬,盛志勇.CD_(14)^+单核细胞人类白细胞抗原-DR预测脓毒症预后及指导免疫调理治疗的初步临床研究[J].中国危重病急救医学,2003,15(3):135-138. 被引量:100
  • 7Volk HD,Reinke P,Krausch D,et al.Monocyte deactivationrationale for a new therapeutic strategy in sepsis[J].Intensive Care Med,1996,22(4):S474-481.
  • 8Vincent JL,De Mendonca A,Cantraine F,et al.Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units:results of a multicentric,prospective study[J].Crit Care Med,1998,26:1793-1800.

二级参考文献2

  • 1J. C. Marshall. Clinical trials of mediator-directed therapy in sepsis: what have we learned?[J] 2000,Intensive Care Medicine(1):S075~S083
  • 2H. -D. Volk,P. Reinke,D. Krausch,H. Zuckermann,K. Asadullah,J. M. Müller,W. -D. D?cke,W. J. Kox. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis[J] 1996,Intensive Care Medicine(4):S474~S481

共引文献99

同被引文献85

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部